Bolt Biotherapeutics financials
$3.60+4.04%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0K | $26.0K | $2.5M | $2.2M | $1.8M | $1.2M | $0.00 | $1.1M | $1.3M | $5.3M | $2.1M | $2.5M |
| Gross profit | $5.0K | $26.0K | $2.5M | $2.2M | $1.8M | $1.2M | $0.00 | $1.1M | $1.3M | $5.3M | $2.1M | $2.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$8.4M | -$7.6M | -$7.1M | -$7.7M | -$9.2M | -$12.1M | -$16.9M | -$16.4M | -$22.6M | -$17.1M | -$19.8M | -$18.2M |
| Net income | -$7.7M | -$7.2M | -$6.6M | -$7.1M | -$8.6M | -$11.0M | -$15.9M | -$15.2M | -$21.2M | -$10.8M | -$17.9M | -$16.3M |
| Net margin | −154400.0% | −27861.5% | −265.2% | −329.4% | −474.6% | −903.4% | — | −1330.1% | −1662.4% | −205.0% | −857.0% | −643.1% |
| Diluted EPS | $-4.57 | $-4.31 | $-3.84 | $-3.72 | $-4.46 | $-5.76 | $-2.88 | $-7.93 | $-11.12 | $-5.60 | $-9.44 | $-8.60 |
| EBITDA | -$7.4M | -$7.4M | -$5.3M | -$7.4M | -$8.9M | -$11.7M | -$15.2M | -$16.0M | -$18.6M | -$16.6M | -$19.3M | -$17.7M |
| Operating cash flow | -$6.5M | -$8.0M | -$7.2M | -$9.7M | -$9.6M | -$13.4M | -$14.4M | -$14.0M | -$16.1M | -$16.8M | -$14.3M | -$16.7M |
| Free cash flow | -$6.6M | -$8.0M | -$7.2M | -$9.8M | -$9.6M | -$13.4M | -$14.4M | -$14.0M | -$16.1M | -$16.8M | -$14.3M | -$16.9M |
| Diluted shares | 1.7M | 1.7M | 1.7M | 1.9M | 1.9M | 1.9M | 5.5M | 1.9M | 1.9M | 1.9M | 1.9M | 1.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.9M | $11.6M | $11.7M | $17.8M | $9.6M | $8.4M |
| Short-term investments | $4.7M | $11.3M | $15.8M | $14.2M | $25.2M | $30.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $40.3M | $48.0M | $56.7M | $65.1M | $75.5M | $85.9M |
| Total liabilities | $27.7M | $28.2M | $30.2M | $33.0M | $36.7M | $39.1M |
| Shareholders' equity | $12.6M | $19.8M | $26.5M | $32.1M | $38.8M | $46.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology